Aberrant sialylation is increasingly recognized as a near universal feature of cancer cells, and ST6Gal-I–mediated sialylation is implicated in promoting cancer hallmarks and modulating pathways intrinsic to tumor cell biology (27, 28, 77). This evidence concerns the gene ST6GAL1 and cancer.